Secondary-immunodeficiency In Blood Cancer
We would like to speak with physicians ( hematologist-oncologists, immunologists, and infectious disease specialists) involved in the diagnosis, treatment, and ongoing management of patients with sid that is associated with chronic lymphocytic leukemia (cll), multiple myeloma (mm), or non-hodgkin’s lymphoma (nhl).
We are aiming to carry out message testing to identify messages that are most compelling to physicians with respect to the diagnosis and treatment of secondary immune deficiency (sid) associated with hematological cancers.
This is a 75-minutes paid phone consultation and a 10 minutes pre-task. If open to participating, please provide a brief answer to the screener below:
1. Do you see at least 10 patients per month with secondary immunodeficiency (sid) associated with chronic lymphocytic leukemia (cll), multiple myeloma, or non-hodgkin’s lymphoma (nhl)?
Please note that we are only interested in your personal point of view and are not seeking confidential information.
Referrals are highly appreciated
+6 Other Responses
Cancer Development Program
Looking for a study coordinator with the ability to grow into the scientific lead for a cancer development program.
We are looking for an experienced study coordinator with an advanced degree who can grow into a scientific leadership position in this program. This would be an ideal position for someone with an advanced degree who has the appropriate educational credentials to assume a leadership role to start on the ground floor of a new drug development program and eventually assume responsibility for the program.
Initially, tasks involve:
assisting with the generation and filing of the ind and regulatory oversight. This includes supervised participation in:
o writing the protocol
o writing the investigators brochure
o assuring the overall adequacy of the filing
o assisting in getting the study sites recruited and ready to access patients.
O overseeing the execution of the protocol to assure a successful clinical trial.
Supporting an expanded access program in europe.
Omd or ph.D inter-medical discipline.
O clinical experience preferred.
Following the completion of the first clinical trial it is expected that this individual would assume an expanded leadership role going forward.+26 Other Responses